ATE340580T1 - Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen - Google Patents

Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen

Info

Publication number
ATE340580T1
ATE340580T1 AT04734005T AT04734005T ATE340580T1 AT E340580 T1 ATE340580 T1 AT E340580T1 AT 04734005 T AT04734005 T AT 04734005T AT 04734005 T AT04734005 T AT 04734005T AT E340580 T1 ATE340580 T1 AT E340580T1
Authority
AT
Austria
Prior art keywords
sub
group
estrogen
inhibitors
formula
Prior art date
Application number
AT04734005T
Other languages
English (en)
Inventor
Bennink Herman Jan Ti Coelingh
Evert Johannes Bunschoten
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of ATE340580T1 publication Critical patent/ATE340580T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT04734005T 2003-05-22 2004-05-19 Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen ATE340580T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03076555 2003-05-22

Publications (1)

Publication Number Publication Date
ATE340580T1 true ATE340580T1 (de) 2006-10-15

Family

ID=33462160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04734005T ATE340580T1 (de) 2003-05-22 2004-05-19 Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen

Country Status (13)

Country Link
US (1) US20060276414A1 (de)
EP (1) EP1624878B1 (de)
CN (1) CN100431545C (de)
AT (1) ATE340580T1 (de)
CA (1) CA2526338C (de)
CY (1) CY1105766T1 (de)
DE (1) DE602004002591T9 (de)
DK (1) DK1624878T3 (de)
ES (1) ES2274456T3 (de)
PL (1) PL1624878T3 (de)
PT (1) PT1624878E (de)
SI (1) SI1624878T1 (de)
WO (1) WO2004103377A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1526856B1 (de) 2002-07-12 2008-01-02 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
US20080287408A1 (en) * 2007-05-14 2008-11-20 Drugtech Corporation Endometriosis treatment
CA2698814A1 (en) * 2007-09-17 2009-03-26 Preglem S.A. Treatment of oestrogen dependant conditions in pre-menopausal women
CN103703014A (zh) 2011-06-01 2014-04-02 埃斯特拉公司 用于产生雌四醇中间体的方法
EA025511B1 (ru) 2011-06-01 2016-12-30 Эстетра С.П.Р.Л. Способ получения промежуточных соединений эстетрола
EP2383279A1 (de) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Herstellungsverfahren für Esterol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
LT3701944T (lt) 2015-06-18 2022-04-11 Estetra Srl Burnoje disperguojamas dozavimo vienetas, kurio sudėtyje yra estetrolio komponentas
JP6813150B2 (ja) 2015-06-18 2021-01-13 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロールを含有する口腔内崩壊錠
ES2671160T3 (es) 2015-06-18 2018-06-05 Mithra Pharmaceuticals S.A. Unidad de dosificación orodispersable que contiene un componente estetrol
PL3310345T3 (pl) * 2015-06-18 2021-10-18 Estetra Sprl Ulegająca rozpadowi w jamie ustnej tabletka zawierająca estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
SG11202009725XA (en) 2018-04-19 2020-11-27 Estetra Sprl Compounds and their uses for alleviating menopause-associated symptoms
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CA3098601A1 (en) * 2018-05-02 2019-11-07 Estetra Sprl Treatment of advanced estrogen receptor positive breast cancer
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2834712A (en) * 1953-05-27 1958-05-13 American Home Prod Urinary estrogen compositions and methods for preparing them
US2753290A (en) * 1953-08-06 1956-07-03 Olin Mathieson Microbiological production of 7-and 15-hydroxy-progesterones
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3487152A (en) * 1967-02-07 1969-12-30 Hoffmann La Roche Tablets containing 7 - chloro - 2 - methylamino - 5 - phenyl - 3h - 1,4 - benzodiazepine-4-oxide and conjugated estrogenic substances
US3608075A (en) * 1969-07-28 1971-09-21 American Home Prod Compositions and methods of treating the menopausal syndrome
YU243975A (en) * 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
FR2377419A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 11b-substitues 1,3,5 (10) trieniques, leur procede de preparation et leur application comme medicament
US4937238A (en) * 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5270172A (en) * 1991-04-26 1993-12-14 Dekk-Tek, Inc. Method to predict tumor response to therapy
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US6613757B1 (en) * 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
US6170058B1 (en) * 1997-12-23 2001-01-02 Arcot Systems, Inc. Method and apparatus for cryptographically camouflaged cryptographic key storage, certification and use
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
GB0005257D0 (en) * 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
RU2180570C1 (ru) * 2000-09-25 2002-03-20 Писаревский Юрий Леонидович Способ лечения болевого синдрома при дисфункциях височно-нижнечелюстного сустава у женщин
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof

Also Published As

Publication number Publication date
CN1816340A (zh) 2006-08-09
PL1624878T3 (pl) 2007-01-31
EP1624878B1 (de) 2006-09-27
ES2274456T3 (es) 2007-05-16
CN100431545C (zh) 2008-11-12
US20060276414A1 (en) 2006-12-07
CA2526338A1 (en) 2004-12-02
DE602004002591T2 (de) 2007-08-09
EP1624878A1 (de) 2006-02-15
CA2526338C (en) 2012-09-25
PT1624878E (pt) 2007-01-31
DE602004002591D1 (de) 2006-11-09
WO2004103377A1 (en) 2004-12-02
DE602004002591T9 (de) 2008-01-03
CY1105766T1 (el) 2011-02-02
SI1624878T1 (sl) 2007-02-28
DK1624878T3 (da) 2007-01-08

Similar Documents

Publication Publication Date Title
ATE340580T1 (de) Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
WO2002094275A8 (en) Use of estrogen compounds to increase libido in women
DK1446128T3 (da) Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling
NO20072286L (no) Hemming av HCV NS3-NS4A-protease
DK0462189T3 (da) Kombinationsterapi til behandling af østrogenfølsomme sygdomme
NO20071264L (no) Cyklopaminanaloger og fremgangsmater for anvendelse derav.
HUP0203304A2 (hu) Prosztatarák megelőzésére szolgáló kemoterápiás módszer és készítmény
DE60335957D1 (de) Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
DE69926400D1 (de) Zusammensetzung enthaltend insulin-sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
ATE449606T1 (de) Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
NO20062679L (no) Nye 17 β -hydroksysteroid-dehydrogenase-type 1-inhibitorer
ATE460413T1 (de) Substituierte 1-propinoyl-piperazine mit affinität für den mglur5 rezeptor zur behandlung von schmerzzuständen
DE60334711D1 (de) Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
IS7517A (is) Efnasambönd sem nýtast í meðferð við miltisbrandiog hindra banvænan þátt
ATE481973T1 (de) Verfahren zur behandlung einer akuten gefässerkrankung
EP1840185A4 (de) Flüssigkristalline zusammensetzung
DE60216239T8 (de) Verwendung von Cyclohexenon-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Dysurie
ATE451922T1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
BRPI0412118A (pt) métodos para melhorar a absorção de aminoácidos, para reduzir a absorção da glicose plasmática, e para prevenir, inibir ou aliviar uma condição de elevado teor de glicose em um vertebrado, e, uso de akg, derivados ou metabólitos de akg, análogos de akg, ou misturas destes
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола
Ahmed et al. First report of the investigation into the importance of pKa in the inhibition of estrone sulfatase by sulfamate containing compounds
DE502004010950D1 (de) Verwendung von alkyl-oligoglykosidcarboxylaten in mitteln zur behandlung keratinischer fasern
ATE288755T1 (de) Tetrahydrochinolin-derivate zur behandlung von krankheiten ausgelöst durch zu hohem oder zu niedrigem oestrogenspiegel
BR9807767A (pt) Composição para o tratamento ou prevenção de câncer da pr;ostata, e uso de um composto, e, uso de n- [ 1 - metil - 1 - ( 4 - metoxifenil ) etil ] - 3 - oxo - 4 - aza - 5 - alfa-androst - 1 - eno - 17 - beta-carboxamida.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1624878

Country of ref document: EP